Sponsored

A Changing Treatment Landscape for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

December 4th 2025

A visual journey into AKT inhibition

November 10th 2025

This content was funded by AstraZeneca and is intended for US healthcare professionals only.

AI in oncology: Fundamentals to full integration into your practice

September 26th 2025

Explore Tempus' latest advancements in artificial intelligence and how it is being applied in real-world oncology settings with Dr. Sanjay Juneja of Tempus and Dr. Debra Patt of Texas Oncology.

From the Top: An Oncologist's Perspective on Advances in Locally Advanced Head and Neck Squamous Cell Carcinoma

September 5th 2025

Can Maintenance Therapy Help Extend Response in Extensive-Stage Small Cell Lung Cancer?

August 29th 2025

In extensive-stage small cell lung cancer, maintenance therapy is under investigation as a strategy to help delay progression, an area of critical importance in an aggressive, relapsing disease.

How Can We Continue Improving Survival Rates for Certain gBRCAm Breast Cancer Patients? A Q&A with AstraZeneca’s Carlos Doti

July 15th 2025

Gene Mutation Could Be Target for ‘Ultrapersonalized’ Therapies in Colon Cancer

June 26th 2025

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene that may play an important role in colon cancer.

DecisionDx®-Melanoma is designed to identify cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy without experiencing early recurrence

June 18th 2025

Sponsored content by Castle Biosciences, Inc. Dr. Guenther has not been compensated in connection with this article; Dr. Guenther receives compensation for his participation on the Speaker’s bureau for Castle Biosciences.

For the First Time, A Nilotinib Without Fasting Restrictions

June 16th 2025

Transforming Colorectal Cancer Care: The Critical Role of Biomarker Testing in Early Detection and Disease Management

June 3rd 2025

Sponsored Content by Pfizer, Inc.

ADC Cast: ADC antigen targets: What are we aiming at?

May 22nd 2025

This is a featured episode from an educational podcast series with expert discussions on antibody drug conjugates, intended for US healthcare professionals.

The Risk of Recurrence in HR+/HER2- Early Breast Cancer

April 14th 2025

Author(s): Sponsored by Novartis

Protecting Patients: Counterfeit Drugs in Oncology and the Fight Against Them

April 8th 2025

Raising the Bar in the First-Line Treatment of EGFR+* mNSCLC Advanced Lung Cancer

March 31st 2025

Managing Unseen Risks: Understanding Recurrence in Early Breast Cancer With No or Limited Nodal Involvement

January 30th 2025

Finding Common Ground: Considerations for Making Treatment Decisions in R/R Follicular Lymphoma

January 27th 2025

Navigating Transitions of Care with a Bispecific Antibody in Relapsed or Refractory Multiple Myeloma

January 22nd 2025

Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer

January 9th 2025

Sponsored Content: Benjamin H. Lowentritt, MD, FACS reviews Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer

Understanding the Patient Experience in Blood Cancer Treatment

December 20th 2024

Embracing Hepatic Artery Infusion Therapy for My Patients with Colorectal Cancer Liver Metastases

December 10th 2024